Displaying 221 - 230 of 535

2021 Consensus Statement on Thyroid Nodule Algorithmic Tool

Co-sponsored by the Associazione Medici Endocrinologi This consensus statement describes the Thyroid Nodule App (termed TNAPP), a novel interactive web-based tool that uses clinical, imaging, cytologic, and molecular marker data to guide clinical decision making to evaluate and manage thyroid nodules. Read Consensus Statement more

2016 Clinical Practice Guideline for the Diagnosis and Management of Thyroid Nodules

Co-sponsored by the Associazione Medici Endocrinologi This guideline covers diagnostic and therapeutic aspects of thyroid nodular disease but not thyroid cancer management. Suggestions for thyroid nodule management during pregnancy and childhood are also included. Read Guideline more

2012 Clinical Practice Guideline for Hypothyroidism in Adults

Co-sponsored by the American Thyroid Association This guideline provides recommendations for diagnosis and clinical management of patients with hypothyroidism in the ambulatory care setting. Read Guideline more

2011 Clinical Practice Guideline for Hyperthyroidism and Other Causes of Thyrotoxicosis

Co-sponsored by the American Thyroid Association This guideline provides evidence-based recommendations for the management of patients with thyrotoxicosis. Read Guideline more

2020 Algorithm on the Management of Dyslipidemia and Prevention of Cardiovascular Disease

This algorithm for the comprehensive management of dyslipidemia and prevention of cardiovascular disease (CVD) complements the 2017 AACE Guideline for Management of Dyslipidemia and Prevention of Cardiovascular Disease and provides clinicians with a practical guide that considers the whole patient, their spectrum of risks and complications, and evidence-based approaches to treatment. An update to this algorithm will be available in late 2025. Read Consensus Statement  … more

2018 Consensus Statement on the Quality of DXA Scans and Reports

This consensus statement identifies common technical errors and issues that can affect DXA report conclusions and provides guidance on how to address those issues to ensure that patients receive appropriate osteoporosis care. Read Consensus Statement more

2018 Position Statement on the Use of Vitamins and Minerals in Skeletal Health

This position statement addresses the use of dietary supplements on skeletal health, the need for more studies that accurately quantify the effect of an individual nutrient on bone health, the importance of recognizing the nutrient needs of each individual, and current understanding of optimal nutrition to maximize bone gain, minimize bone loss, and reduce fragility fracture risk. Read Position Statement more

2022 Clinical Practice Guideline for Development of a Diabetes Mellitus Comprehensive Care Plan

This updated guideline provides recommendations for the care and management of people with or at risk for diabetes mellitus at every stage, including prevention, diagnosis, and treatment. Read Guideline   The authors of the guideline identified a few errata. Download the corrigendum to learn about changes that reflect up-to-date best practice. Download Corrigendum   The… more

2019 Position Statement on Transcultural Diabetes Care in the United States

This position statement presents the proceedings of conferences held by AACE in 2017 with health care professionals and community leaders that focused on improvement of diabetes care for African Americans, Latino/Hispanics, Asian Americans, and Native Americans in the United States. Based on these meetings, AACE created a diabetes care model that promotes educational, research, and clinical practice enhancements, including but not limited to the use of culturally appropriate language, nutritional messaging, health literacy, clinic infrastructure with flexible office hours, behavioral medicine… more

2020 Position Statement on Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem

This position statement raises awareness about the risks of off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements. This statement distinguishes off-label hormone use from legitimate use for diagnoses such as male hypogonadism, growth hormone deficiency, hypothyroidism, and adrenal insufficiency. Read Position Statement more